Intracytoplasmic sperm injection in bovine: effects of oocyte activation, sperm pretreatment and injection technique.
Intracytoplasmic sperm injection (ICSI) is a very important technique for treating male subfertility and for basic research. The efficiency of ICSI in bovine is very limited because of the necessity for additional oocyte activation before or after the ICSI procedure. In this study, we compared the effects of seven different protocols on activation and fertilization rates of bovine oocytes after ICSI and on their subsequent development under in vitro conditions. The protocols include 1) different chemical activation of oocytes, 2) pretreated or nonpretreated sperm, and 3) conventional or Piezo-driven injection techniques. In all three groups, ICSI, sham-injected, and noninjected, the highest activation rates were obtained after treatment of oocytes with ionomycin followed by 6-dimethylaminopurine (6-DMAP). Using this treatment for oocyte activation, 59% of oocytes were activated and 31% of oocytes were fertilized using dithiothreitol (DTT) pretreated spermatozoa and Piezo-driven injection. Using the protocols with the same oocyte activation or activation with calcium ionophore (Ca-I) and cycloheximide (CHX), nonpretreated sperm, and conventional injection technique, early cleavage rate (79.6% and 77.6%, respectively) were significantly (P <0.01) higher when compared with all other protocols. The latter protocol resulted in 8% blastocyst and 90% of the obtained blastocysts were found to be diploid. Our results demonstrate that activation of oocytes, sperm treatment, and injection technique separately or together could improve the success of bovine ICSI.
Suttner
R
R
Department of Molecular Animal Breeding and Genetics, Ludwig-Maximilians University, Munich, Germany.
Zakhartchenko
V
V
Stojkovic
P
P
Müller
S
S
Alberio
R
R
Medjugorac
I
I
Brem
G
G
Wolf
E
E
Stojkovic
M
M
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001562:Benzimidazoles / Q000737:chemistry; D000001:Calcimycin / Q000494:pharmacology; D002417:Cattle / Q000502:physiology*; D004396:Coloring Agents / Q000737:chemistry; D003513:Cycloheximide / Q000494:pharmacology; D004247:DNA / Q000737:chemistry / Q000302:isolation & purification; D017931:DNA Primers / Q000737:chemistry; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D005456:Fluorescent Dyes / Q000737:chemistry; D015759:Ionomycin / Q000494:pharmacology; D007476:Ionophores / Q000494:pharmacology; D007621:Karyotyping; D016018:Least-Squares Analysis; D008297:Male; D009865:Oocytes / Q000502:physiology*; D010078:Oxazines / Q000737:chemistry; D011003:Ploidies; D016133:Polymerase Chain Reaction / Q000662:veterinary; D012150:Polymorphism, Restriction Fragment Length; D012732:Sex Determination Analysis / Q000662:veterinary; D020554:Sperm Injections, Intracytoplasmic / Q000379:methods / Q000662:veterinary*; D013084:Sperm-Ovum Interactions / Q000502:physiology*; D013094:Spermatozoa / Q000502:physiology*
D001562:Benzimidazoles; D004396:Coloring Agents; D017931:DNA Primers; D004791:Enzyme Inhibitors; D005456:Fluorescent Dyes; D007476:Ionophores; D010078:Oxazines; C018437:aceto-orcein; D000001:Calcimycin; D015759:Ionomycin; C001020:N(6),N(6)-dimethyladenine; D004247:DNA; D003513:Cycloheximide; D000225:Adenine; C017807:bisbenzimide ethoxide trihydrochloride